Canadian Dry Eye: Not the Ginger

Interview with Mahnia Madan, OD.   Dr. Mahnia Madan brings her knowledge of practicing in both the US and Canada to the table. This podcast is dedicated to our listeners across the border who may have questions about scope of practice and available treatments in Canada.  Find out what unique options make Canada special.

“About the Sponsor”:

Santen

As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen's websites www.santenusa.com and www.santen.com (Japan headquarters).

Kala

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.  The Company also has a pipeline of proprietary NCE development programs targeted to address unmet medical needs, including both front and back of the eye diseases.